Crestwood Advisors Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $994K | Buy |
23,297
+2,585
| +12% | +$140K | 0.01% | 322 |
|
|
2026
Q1 | $1.3M | Sell |
20,712
-2,117
| -9% | -$169K | 0.02% | 274 |
|
|
2025
Q4 | $2.18M | Sell |
22,829
-3,519
| -13% | -$345K | 0.04% | 211 |
|
|
2025
Q3 | $2.57M | Sell |
26,348
-54,095
| -67% | -$5.6M | 0.04% | 188 |
|
|
2025
Q2 | $8.64M | Sell |
80,443
-975
| -1% | -$98.7K | 0.15% | 113 |
|
|
2025
Q1 | $8.21M | Buy |
81,418
+13,490
| +20% | +$1.36M | 0.16% | 107 |
|
|
2024
Q4 | $6.07M | Buy |
67,928
+1,397
| +2% | +$123K | 0.11% | 119 |
|
|
2024
Q3 | $5.58M | Buy |
66,531
+810
| +1% | +$63.9K | 0.11% | 120 |
|
|
2024
Q2 | $5.06M | Buy |
65,721
+192
| +0.3% | +$14.1K | 0.1% | 119 |
|
|
2024
Q1 | $4.49M | Buy |
65,529
+3,164
| +5% | +$203K | 0.1% | 124 |
|
|
2023
Q4 | $3.61M | Sell |
62,365
-717
| -1% | -$38.3K | 0.08% | 137 |
|
|
2023
Q3 | $3.33M | Buy |
63,082
+2,733
| +5% | +$143K | 0.09% | 131 |
|
|
2023
Q2 | $3.26M | Buy |
60,349
+2,844
| +5% | +$149K | 0.1% | 94 |
|
|
2023
Q1 | $2.88M | Sell |
57,505
-3,000
| -5% | -$141K | 0.1% | 102 |
|
|
2022
Q4 | $2.8M | Sell |
60,505
-679
| -1% | -$29.4K | 0.1% | 103 |
|
|
2022
Q3 | $2.37M | Sell |
61,184
-55
| -0.1% | -$2.21K | 0.08% | 110 |
|
|
2022
Q2 | $2.28M | Sell |
61,239
-190
| -0.3% | -$7.73K | 0.08% | 114 |
|
|
2022
Q1 | $2.72M | Sell |
61,429
-709
| -1% | -$30.7K | 0.08% | 112 |
|
|
2021
Q4 | $2.64M | Buy |
62,138
+29
| +0% | +$1.22K | 0.07% | 115 |
|
|
2021
Q3 | $2.69M | Hold |
62,109
| – | – | 0.08% | 115 |
|
|
2021
Q2 | $2.66M | Hold |
62,109
| – | – | 0.08% | 114 |
|
|
2021
Q1 | $2.4M | Sell |
62,109
-813
| -1% | -$30.8K | 0.08% | 114 |
|
|
2020
Q4 | $2.26M | Buy |
62,922
+52,352
| +495% | +$1.89M | 0.07% | 115 |
|
|
2020
Q3 | $404K | Hold |
10,570
| – | – | 0.02% | 178 |
|
|
2020
Q2 | $371K | Sell |
10,570
-22
| -0.2% | -$792 | 0.01% | 185 |
|
|
2020
Q1 | $346K | Sell |
10,592
-1,328
| -11% | -$51.9K | 0.02% | 170 |
|
|
2019
Q4 | $539K | Sell |
11,920
-475
| -4% | -$19.9K | 0.02% | 172 |
|
|
2019
Q3 | $504K | Sell |
12,395
-400
| -3% | -$16.9K | 0.02% | 167 |
|
|
2019
Q2 | $550K | Buy |
12,795
+4,750
| +59% | +$183K | 0.02% | 157 |
|
|
2019
Q1 | $309K | Hold |
8,045
| – | – | 0.02% | 138 |
|
|
2018
Q4 | $284K | Sell |
8,045
-576
| -7% | -$20.9K | 0.02% | 133 |
|
|
2018
Q3 | $332K | Hold |
8,621
| – | – | 0.02% | 125 |
|
|
2018
Q2 | $287K | Sell |
8,621
-8,848
| -51% | -$267K | 0.02% | 134 |
|
|
2018
Q1 | $477K | Sell |
17,469
-3,902
| -18% | -$106K | 0.04% | 105 |
|
|
2017
Q4 | $530K | Sell |
21,371
-476
| -2% | -$13.1K | 0.04% | 107 |
|
|
2017
Q3 | $637K | Hold |
21,847
| – | – | 0.05% | 94 |
|
|
2017
Q2 | $590K | Sell |
21,847
-125
| -0.6% | -$3.32K | 0.05% | 94 |
|
|
2017
Q1 | $584K | Buy |
21,972
+11,022
| +101% | +$268K | 0.05% | 90 |
|
|
2016
Q4 | $237K | Hold |
10,950
| – | – | 0.02% | 140 |
|
|
2016
Q3 | $261K | Sell |
10,950
-1,344
| -11% | -$32.1K | 0.03% | 110 |
|
|
2016
Q2 | $287K | Sell |
12,294
-4,050
| -25% | -$87.6K | 0.04% | 108 |
|
|
2016
Q1 | $307K | Buy |
16,344
+5,694
| +53% | +$100K | 0.04% | 109 |
|
|
2015
Q4 | $196K | Sell |
10,650
-550
| -5% | -$9.86K | 0.02% | 145 |
|
|
2015
Q3 | $184K | Sell |
11,200
-10,400
| -48% | -$178K | 0.02% | 136 |
|
|
2015
Q2 | $382K | Buy |
+21,600
| New | +$386K | 0.05% | 105 |
|
Other funds holding BSX
Crestwood Advisors Group's BSX Position: Q2 2026 in Review
Crestwood Advisors Group increased its Boston Scientific (BSX) stake by 12% in Q2 2026, buying an estimated $140K and bringing the position to 23,297 shares worth $994K. The position accounts for 0.01% of the portfolio, ranked #322.
Crestwood Advisors Group first reported a position in BSX in Q2 2015 and has held it in 45 quarters since. The position peaked at $8.64M in Q2 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Crestwood Advisors Group held 23,297 shares of Boston Scientific worth $994K as of Q2 2026.
- Crestwood Advisors Group bought 2,585 Boston Scientific shares in Q2 2026, an estimated $140K.
- Boston Scientific made up 0.01% of Crestwood Advisors Group's portfolio in Q2 2026, its #322 holding.
- Crestwood Advisors Group first reported a position in Boston Scientific in Q2 2015 and has held it in 45 quarters since.
- Crestwood Advisors Group's Boston Scientific position peaked at $8.64M in Q2 2025.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Crestwood Advisors Group's 13F filing for Q2 2026, filed 3 Aug 2026.